News Lilly allies with gene-editing firm Seamless on hearing loss Gene-editing firm Seamless Therapeutics has attracted its first major pharma partner, Eli Lilly, with a $1.12bn alliance focused on hearing loss.
News CRISPR biotech Intellia plummets as trial paused for safety Intellia lost 45% of its value today as phase 3 trials of one of its priority drug programmes were halted due to a patient being hospitalised.
News SpliceBio gathers $135m for eye disease gene therapies Spain's SpliceBio has raised $135m in financing that will help it move a gene-editing therapy for Stargardt disease through clinical testing.
News World first as infant gets personalised CRISPR therapy In a medical breakthrough, a child diagnosed with a rare genetic disorder has received a bespoke CRISPR gene editing therapy to correct the mutation.
News Beam launches $500m financing on base-editing trial data Beam says its base-editing drug has met its goals in a phase 1/2 trial in genetic disease AATD, and it wants to raise $500m to take it forward.
News Sickle cell gene therapy Casgevy finally cleared for NHS use Vertex's gene-editing therapy for sickle cell disease, Casgevy, has been given the nod for use by the NHS in England after an earlier rejection.
News New UK PM shuts down science and tech department In the midst of appointing his Cabinet, new UK Prime Minister Andy Burnham has scrapped the Department for Science, Innovation and Technology (DSIT).
Digital Sponsored Discover a new era of healthcare panel engagement: Grounded ... A new webinar from Konovo will address some of the critical topics impacting today’s healthcare market research industry.